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1. Introduction
Forced degradation studies are also known as stress testing, stress studies, stress decomposition studies, forced 
decomposition studies, etc. Forced degradation is a process that involves degradation of drug products and drug substances 
at  conditions  more  severe  than  accelerated  conditions and thus generates  degradation  products  that  can  be studied  to  
determine  the  stability of  the  molecule.  The ICH guideline  states  that  stress  testing is  intended to identify the  likely 
degradation  products  which  further  helps  in  determination  of  the  intrinsic  stability  of  the  molecule  and  establishing 
degradation pathways, and to validate the stability indicating procedures used [1]. But these guidelines are very general in 
conduct of forced degradation and do not provide details about the practical approach towards stress testing. Although  
forced
Degradation  studies  area  regulatory  requirement  and  scientific  necessity  during  drug  development,  it  is  not 
considered as a requirement for formal stability program. 
It has become mandatory to perform stability studies of new drug moiety before filing in registration dossier. The  
FDA and ICH guidances state the requirement of stability testing data to understand how the quality of a drug substance and 
drug product changes with time under the influence of various environmental factors. The stability studies include long term 
studies (12months) and accelerated stability studies (6months).But  intermediate studies (6months) can be performed at  
conditions milder than that used in accelerated studies. So the study of degradation products like separation, identification  
and quantitation would take even more time. As compared to stability studies, forced degradation studies help in generating 
degradants in much shorter span of time, mostly a few weeks.
2. Objective of forced degradation studies 
Forced degradation studies are carried out to achieve the following purposes: 
1. To establish degradation pathways of drug substances and drug products.
2. To differentiate degradation products that  are related to drug products from those that  are generated from non-drug  
product in a formulation. 
Abstract
Forced  degradation  studies  show the  chemical  behavior  of  the  molecule 
which  in  turn  helps  in  the  development  of  formulation  and  package.  A forced 
degradation study is an essential step in the design of a regulatory compliant stability 
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requirement in ICH Guideline Q1A in 1993. Forced degradation is a degradation of 
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also provides an insight into degradation pathways and degradation products of the 
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studies by providing a strategy for conducting studies on degradation mechanisms.
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3. To elucidate the structure of degradation products. 
4. To determine the intrinsic stability of a drug substance in formulation.
5. To reveal the degradation mechanisms such as hydrolysis, oxidation, thermolysis or photolysis of the drug substance and  
drug product [1,2]. 
6. To establish stability indicating nature of a developed method. 
7. To understand the chemical properties of drug molecules.
8. To generate more stable formulations. 
9. To produce a degradation profile  similar  to  that  of  what  would be observed in a  formal stability study under ICH  
conditions. 
10. To solve stability-related problems [3]
3. Overview of Regulatory Guidance
Force  degradation  studies  are  described  various  International  guidelines.  The  International  committees  for 
Harmonization of Technical Requirements for Registration of pharmaceutical Human use (ICH)  has published a set of 
guidelines  which have  been  discussed,  agreed  upon and adopted by the American,  European  and Japanese regulatory 
authorities. In the majority of cases, the ICH guidelines only apply to the marketing applications for new products, i.e they 
do not apply during clinical development. However, since the conditions used for forced degradation are only defined in  
general terms, it is possible to apply them for developing stability indicating methods during clinical development. The  
same forced degradation conditions can then be applied to the drug substance during development and commercialization. 
The ICH guidelines that are applicable to forced degradation studies are 4-8
ICH Q1A  Stability Testing of New Drug Substances and Products
ICH Q1B  Photo stability Testing of New Drug Substances and Products
ICH Q2B  Validation of Analytical Procedures: Methodology
In ICH Q1A, section 2.1.2 (Stress Testing), there are recommended conditions for performing forced degradation 
studies on drug substances and drug products. The recommendations are to examine the effects of temperature (above that 
for accelerated testing, i.e., >50 C), humidity ( 75% relative humidity), oxidation and photolysis. Testing in solution should 
also be performed across a wide pH range either as a solution or suspension. These samples are then used to develop a 
stability-indicating method ICH Q1B gives recommended approaches to assessing the photo stability of drug substances 
and drug products. Forced degradation conditions are specified in Section II (drug substance) and Section III (drug product).  
Exposure  levels  for  forced  degradation  studies  are  not  defined,  although  they  can  be  greater  than  that  specified  for  
confirmatory (stability testing.  The actual  design  of  photo stability studies  is  left  to  the  applicant;  however,  scientific  
justification is required where light exposure studies are terminated after a short time, e.g., where excessive degradation is  
observed. Photo stability testing can be performed on the solid or in solution/suspension. These samples are then used to 
develop a stability indicating method. Both guidances Q1A and Q1B, note that some of the degradation products formed  
during forced degradation studies may not actually be observed to form during stability studies, in which case they need not  
be examined further. ICH Q2B gives guidance on how to validate analytical methodology and in section B 1.2.2 (impurities 
not available) there is a recommendation to use samples from forced degradation studies to prove specificity. Specificity is a  
key factor in determining whether or not the analytical method is stability indicating. Co-elution of peaks or components  
being retained on the column will underestimate the amount of degradation products formed and could compromise quality  
and increase risk to the patient. Q3A (R2 requires identification of each impurity with respect to both chemistry and safety 
perspectives. The chemistry perspectives include classification and identification of impurities, report generation, listing of 
impurities in specification and a brief discussion of analytical procedures while the safety perspectives include specific  
guidance for qualifying those impurities that were not present or were present at substantially lower levels in batch of a new  
drug substance and used in safety and clinical studies 9-15.
3.1 Forced degradation performed:  It  is very important to know when to perform forced degradation studies for the 
development of new drug substance and new drug product. FDA guidance states that stress testing should be performed in 
phase III of regulatory submission process. Stress studies should be done in different pH solutions, in the presence of  
oxygen and light, and at elevated temperatures and humidity levels to determine the stability of the drug substance. These  
stress  studies  are conducted  on a single  batch.  The results  should be  summarized  and  submitted  in  an  annual  report.  
However, starting stress testing early in preclinical phase or phase I of clinical trials is highly encouraged and should be  
Jitendra Kumar et al / International Journal of Advances in Pharmaceutics  2 (3) 2013                                                    36 
conducted on drug substance to obtain sufficient time for identifying degradation products and structure elucidation as well 
as optimizing the stress conditions. An early stress study also gives timely recommendations for making improvements in  
the manufacturing process and proper selection of stability-indicating analytical procedures [16,17].
3.2 Origin of degradation products: The main reason of appearance of impurities in drug substance or product is due to its 
degradation. The chemical instability of the drug substance under the conditions of heat, humidity, solvent, pH, and light 
encountered during manufacture, isolation, puri cation, drying, storage, transportation, and/or formulation is main cause of  
its degradation. It is governed by inherent chemical stability of the drug substance. The major routes of degradation of any  
drug  substance  include  hydrolysis,  oxidation,  heat  and  photolysis.  The  stress  testing  helps  in  generation  all  possible  
degradation products that may form under different conditions [4].
3.3  Selection  of  experimental  conditions:  There  are  many examples  in  the  literature  of  experimental  conditions  for 
conducting forced degradation studies and the structural multiplicity of drug molecules makes it not possible to identify a 
generic set of conditions for a forced degradation study. For an early phase molecule, using a set of normal conditions by  
first intention makes sense since very little may be known about the intrinsic stability. If early stability data are available  
which suggest the molecule is labile at a particular condition (e.g., high pH), the conditions can be modified to take into  
account the instability (e.g., reduced temperature or time of study). Once a set of conditions have been found, they may be  
repeated whenever a new stability-indicating method is required during development. Therefore, for later-phase molecules,  
the forced degradation conditions are defined by the earlier work. By reprocess the same forced degradation conditions  
throughout development a consistent approach is maintained. Some conditions mostly used for forced degradation studies 
are presented in Table 1.
Table 1 Conditions mostly used for forced degradation studies
Degradation type Experimental conditions Storage conditions Sampling time (days)
Hydrolysis
Control API (no acid or base)
0.1M HCl
0.1 M NaOH
Acid control (no API)
Base control (no API)
pH: 2,4,6,8
40oC, 60o C
40oC, 60o C
40oC, 60o C
40oC, 60o C
40oC, 60o C
40oC, 60o C
1,3,5
1,3,5
1,3,5
1,3,5
1,3,5
1,3,5
Oxidation
3%H2O2
Peroxide control
Azobisisobutyronitrile (AIBN)
AIBN control
250C, 600 C
250C, 600 C
40oC, 60o C
40oC, 60o C
1,3,5
1,3,5
1,3,5
1,3,5
Photolytic
Light 1 × ICH
Light 3 × ICH
Light control
NA
NA
NA
1,3,5
1,3,5
1,3,5
Thermal
Heat chamber
Heat chamber
Heat chamber
Heat chamber
Heat control
60 0C
60 0C/75% RH
80 0C
80 0C/75% RH
Room temp.
1,3,5
1,3,5
1,3,5
1,3,5
1,3,5
4. Degradation conditions
4.1 Hydrolytic conditions: Hydrolysis is one of the most common degradation chemical reactions over a wide range of pH. 
Hydrolysis is a chemical process that includes decomposition of a chemical compound by reaction with water. Hydrolytic  
study under acidic and basic condition involves catalysis of ionizable functional groups present in the molecule. Acid or 
base  stress  testing  involves  forced  degradation  of  a  drug  substance  by exposure  to  acidic  or  basic  conditions  which 
generates primary degradants in desirable range. The selection of the type and concentrations of acid or base depends on the 
stability of the drug substance. Hydrochloric acid or sulfuric acids (0.1–1 M) for acid hydrolysis and sodium hydroxide or 
potassium hydroxide (0.1–1M) for base hydrolysis are suggested as suitable reagents for hydrolysis [8,18]. If the compounds 
for stress testing are poorly soluble in water, then co-solvents can be used to dissolve the min HCl or NaOH. The selection  
of co-solvent is based on the drug substance structure. Stress testing trial is normally started at room temperature and if  
there is no degradation, elevated temperature (50–70 1C) is applied. Stress testing should not exceed more than 7days. The 
degraded sample is then neutralized using suitable acid, base or buffer, to avoid further decomposition.
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4.2 Oxidation conditions: Hydrogen peroxide is widely used for oxidation of drug substances in forced degradation studies 
but other oxidizing agents such as metal ions, oxygen, and radical initiators (e.g.,azobisisobutyronitrile, AIBN) can also be 
used. Selection of an oxidizing agent, its concentration, and conditions depends on the drug substance. It is reported that  
subjecting the solutions to  0.1–3% hydrogen per  oxide at  neutral  pH and room temperature for  seven days  or  upto a  
maximum 20% degradation could potentially generate relevant degradation products [18]. The oxidative degradation of drug 
substance involves an electron transfer mechanism to form reactive anions and cations. Amines, sulfides and phenols are  
susceptible to electron transfer oxidation to give N-oxides, hydroxylamine, sulfones and sulfoxide [19]. The functional group 
with labile hydrogen like benzylic carbon, allylic carbon, and tertiary carbon or α-positions with respect to hetroatom is 
susceptible to oxidation to form hydroperoxides, hydroxide or ketone.
4.3 Photolytic conditions:  The photo stability testing of drug substances must be evaluated to demonstrate that a light 
exposure does not result in unacceptable change. Photo stability studies are performed to generate primary degradants of 
drug substance by exposure to UV or fluorescent conditions. Some recommended conditions for photostability testing are 
described in ICH guidelines [20]. Samples of drug substance and solid/liquid drug product should be exposed to a minimum 
of 1.2million lx h and 200 W h/m2 light. The most commonly accepted wavelength of light is in the range of 300– 800 nm 
to cause the photolytic degradation[21,22]. The maximum illumination recommended is 6 million lx h. Light stress conditions 
can induce photo oxidation by free radical mechanism. Functional groups like carbonyls, nitroaromatic, N-oxide, alkenes, 
aryl chlorides, weak C–H and O–H bonds, sulfides and polyenes are likely to introduce drug photosensitivity.
4.4  Thermal  conditions:  Thermal  degradation  (e.g.,  dry heat  and  wet  heat)  should be  carried  out  at  more  strenuous 
conditions than recommended ICH Q1A accelerated testing conditions. Samples of solid-state drug sub- stances and drug 
products should be exposed to dry and wet heat, while liquid drug products should be exposed to dry heat. Studies may be  
conducted at higher temperatures for a shorter period [18]. Effect of temperature on thermal degradation of a substance is 
studied through the Arrhenius equation:
               k = Ae-Ea/RT 
where k is specific reaction rate, A is frequency factor, Ea is energy of activation, R is gas constant (1.987cal/degmole) and  
T is absolute temperature . Thermal degradation study is carried out at 40–80oC.
4.5 Humidity:  Humidity is  the  Key factor  in  establishing the  potential  degradants  in  the  finished  product  and active 
pharmaceutical ingredient. Normally 90% Humidity for duration of one week shall be recommended for the establishment  
of forced degradation samples.
6. Selection of samples
The strength and duration of the stress conditions need to be decided by experimenting to get the sample with  
required degradation. Simultaneously subjects the Placebo (Excipients mixture) as per the manufacturing formula to all the  
above stress conditions. For multi-drug product placebo formulation containing one drug substance each shall be subjected 
to forced degradation. Prepare test solutions using unstressed sample, placebo and the stressed samples, as per the test  
method and inject into the HPLC system with diode array detector. Record the chromatograms and calculate the Percentage 
degradation and percent net degradation as per acceptance criteria. In case of stable molecules, percent ne degradation may 
be difficult to achieve as per acceptance criteria. Hence based on the experiments, study can be concluded and summary of  
the experiments shall be documented. Demonstrate the effective separation of the analyte from the degradation product and  
peaks if any due to components of placebo mixture. Ensure that response of analyte peak in test solution is equal to or less  
than 1AU (absorbance unit). If it is more, dilute the test solution accordingly and repeat the analysis.
6.1Identification  and characterization  of  drug products  by selected analytical  methods:  The preferred  method of 
analysis for a stability indicating assay is reverse-phase high-performance liquid chromatography (HPLC). RP-HPLC is  
preferred for several reasons, such as its compatibility with aqueous and organic solutions, high precision, sensitivity, and 
ability to detect polar compounds. Separation of peaks can be carried out by selecting appropriate column type, column 
temperature, and making adjustment to mobile phase pH Poorly-retained, highly polar impurities should be resolved from 
the solvent front. As part of method development, a gradient elution method with varying mobile phase composition (very  
low organic composition to high organic composition) may be carried out to capture early eluting highly polar compounds 
and  highly retained non polar compounds.  Stressed samples  can also be  screened with the gradient  method to assess 
potential  elution  pattern.  Sample  solvent  and  mobile  phase  should  be  selected  to  afford  compatibility  with  the  drug  
substance, potential impurities and degradants.
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Stress sample preparation should mimic the sample preparation outlined in the analytical procedure as closely as 
possible. Neutralization or dilution of samples may be necessary for acid and base hydrolyzed samples. Chromatographic 
profiles of stressed samples should be compared to those of relevant blanks (containing no active and unstressed samples to  
determine the origin of peaks. The blank peaks should be excluded from calculations. The amount of impurities (known and 
unknown) obtained under each stress condition should be provided along with the chromatograms (full scale and expanded 
scale showing all the peaks) of blanks, unstressed, and stressed samples Additionally, chiral drugs should be analyzed with  
chiral methods to establish stereo chemical purity and stability. The analytical method of choice should be sensitive enough 
to detect impurities at low levels (i.e., 0.05% of the analyte of interest or lower), and the peak responses should fall within  
the range of detector's linearity 23-27.
Degradation product identification and characterization shall be performed based on stability results in accordance 
with ICH requirements. Conventional methods (e.g., column chromatography) or hyphenated techniques (e.g., LC MS, LC 
NMR) can be used in the identification and characterization of the degradation products. It should be noted that structural  
characterization of degradation products is necessary for those impurities that are formed during formal shelf-life stability 
studies. The detector should contain 3D data capabilities such as diode array detectors or mass spectrometers to be able to 
detect spectral non- homogeneity. After the method finalization test method on different detectors like RI/ELSD/CE detector 
with the suitable method parameters and compare the data with other detectors like UV, Fluorescence etc. The UV inactive  
compounds can be found with this exercise. If any such type of components are there these shall be addressed based on the  
process and cross checking to be made by using LC-MS technique 8,9,28-30.
Use the analytical mode for major impurities /degradants and check the mass numbers or develop chromatographic 
conditions suitable to LC-MS and identify the mass of major degradant which are found to be forming greater than 1.0%  
during stress studies. Try to establish the structures of the major degradant, if possible and compare the synthetic process for 
justification.  Diode array detection  also  offers  the  possibility  of  checking  peak  profile  for  multiple  wavelengths.  The 
limitation of diode array arises when the UV profiles are similar for analyte peak and impurity or degradant peak and the  
noise level of the system is high to mask the co-eluting impurities or degradants Compounds of similar molecular weights 
and functional groups such as diastereoisomers may exhibit similar UV profiles. In such cases, attempts must be made to  
modify the chromatographic parameters  to achieve necessary separation. An optimal wavelength should be selected to  
detect and quantitation of all the potential impurities and degradants Use of more than one wavelength may be necessary, if  
there is no overlap in the UV profile of an analyte and impurity or degradant peaks. A valuable tool in method development  
is the overlay of separation signals at different wavelengths to discover dissimilarities in peak profiles.
7. Conclusion
Forced  degradation  studies  of  new  drug  substances  and  drug  products  are  important  to  help  develop  and 
demonstrate specificity of stability-indicating methods and to determine the degradation pathways and degradation products  
of the active ingredients. They were also useful in the investigation of the chemical and physical stability of crystal forms, 
the  stereochemical  stability  of  the  drug  substance  alone  and  in  the  drug  product  and  mass-balance  issues,  and  for  
differentiating drug substance related degradation products in formulations. The ICH not provided any formal guidance.  
Adequate degradation required to understand the probable degradants for the evaluation of stability indicating method.
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